Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib Case report and review of literature from Qatar英文文献资料.docVIP

下载本文档

1
0
约9.33千字
约 4页
2017-05-10 发布于上海
举报
版权申诉

Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib Case report and review of literature from Qatar英文文献资料.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib Case report and review of literature from Qatar英文文献资料

Vol.1, No.1, 1-4 (2012) Modern Chemotherapy /10.4236/mc.2012.11001 Can we achieve complete remission in locally advanced unresectable Hepatocellular Carcinoma (HCC) by using Sorafenib? Case report and review of literature from Qatar Kakil Ibrahim Rasul National Center for Cancer Care and Research (NCCCR), Doha, Qatar; kakil954@ Received 7 May 2012; revised 20 June 2012; accepted 18 July 2012 ABSTRACT increased time to disease progression (5.5 mo vs 2.8 mo) and disease control rate (43% versus 32%). But there is no complete remission in these studies. Overall toxicity did not differ between treatment and placebo arm (52% versus 54%). Based on this trial, sorafenib has become the most promising chemotherapeutic agent in the treat- ment of hepatocellular carcinoma in patients with pre- served liver function. Patients with HCC continue to have a dismal prognosis, with 1-year and 3-year survival rates of 36 and 17%, respectively. This is in part re- lated to more than two-thirds of tumors being diagnosed at advanced stages, as well as a sub- stantial portion of patients with early HCC failing to receive potentially curative treatments. Sys- temic therapy for advanced unresectable HCC limited until the discovery of sorafenib, we are reporting a 53 year patient with unresectable HCC achieved complete remission clinically, radiolo- gically and biochemically with sorafenib which is the first case report. 2. CASE PRESENTATION A 53 years male Egyptian known non insulin depen- dent diabetes mellitus (NIDDM) on Metformin 500 mg orally twice daily since 6 years, and HCV + ve Chronic smoker1pack/day since 35 years On December 2010 dur- ing follow up ultrasound examination found to have fo- cal lesion in the liver He had mild right hypochondrial pain which dull in nature not radiating and no associated symptoms, his ECOG (Eastern Cooperative Oncology Group performance status) PS is 0, Chi